Biogen Picks Up Reata for $7.3B While Alexion Gets Pfizer Programs for $1B

Friday, Biogen announced that it was planning to acquire Reata for approximately $7.3 billion, while Alexion, AstraZeneca’s rare disease subsidiary, announced that it had entered a purchase and license agreement for a portfolio of preclinical gene therapy programs and technologies from Pfizer.
Source: Drug Industry Daily